Literature DB >> 19706884

Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.

Harlan S Robins1, Paulo V Campregher, Santosh K Srivastava, Abigail Wacher, Cameron J Turtle, Orsalem Kahsai, Stanley R Riddell, Edus H Warren, Christopher S Carlson.   

Abstract

The adaptive immune system uses several strategies to generate a repertoire of T- and B-cell antigen receptors with sufficient diversity to recognize the universe of potential pathogens. In alphabeta T cells, which primarily recognize peptide antigens presented by major histocompatibility complex molecules, most of this receptor diversity is contained within the third complementarity-determining region (CDR3) of the T-cell receptor (TCR) alpha and beta chains. Although it has been estimated that the adaptive immune system can generate up to 10(16) distinct alphabeta pairs, direct assessment of TCR CDR3 diversity has not proved amenable to standard capillary electrophoresis-based DNA sequencing. We developed a novel experimental and computational approach to measure TCR CDR3 diversity based on single-molecule DNA sequencing, and used this approach to determine the CDR3 sequence in millions of rearranged TCRbeta genes from T cells of 2 adults. We find that total TCRbeta receptor diversity is at least 4-fold higher than previous estimates, and the diversity in the subset of CD45RO(+) antigen-experienced alphabeta T cells is at least 10-fold higher than previous estimates. These methods should prove valuable for assessment of alphabeta T-cell repertoire diversity after hematopoietic cell transplantation, in states of congenital or acquired immunodeficiency, and during normal aging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19706884      PMCID: PMC2774550          DOI: 10.1182/blood-2009-04-217604

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Non-productive human TCR beta chain genes represent V-D-J diversity before selection upon function: insight into biased usage of TCRBD and TCRBJ genes and diversity of CDR3 region length.

Authors:  B J Manfras; D Terjung; B O Boehm
Journal:  Hum Immunol       Date:  1999-11       Impact factor: 2.850

2.  A direct estimate of the human alphabeta T cell receptor diversity.

Authors:  T P Arstila; A Casrouge; V Baron; J Even; J Kanellopoulos; P Kourilsky
Journal:  Science       Date:  1999-10-29       Impact factor: 47.728

3.  Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor.

Authors:  P Bousso; V Wahn; I Douagi; G Horneff; C Pannetier; F Le Deist; F Zepp; T Niehues; P Kourilsky; A Fischer; G de Saint Basile
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 4.  Aging and T-cell diversity.

Authors:  Jörg J Goronzy; Won-Woo Lee; Cornelia M Weyand
Journal:  Exp Gerontol       Date:  2007-01-10       Impact factor: 4.032

Review 5.  The molecular basis for public T-cell responses?

Authors:  Vanessa Venturi; David A Price; Daniel C Douek; Miles P Davenport
Journal:  Nat Rev Immunol       Date:  2008-03       Impact factor: 53.106

6.  Estimating the number of unseen variants in the human genome.

Authors:  Iuliana Ionita-Laza; Christoph Lange; Nan M Laird
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-10       Impact factor: 11.205

7.  TCR beta-chain sharing in human CD8+ T cell responses to cytomegalovirus and EBV.

Authors:  Vanessa Venturi; Hui Yee Chin; Tedi E Asher; Kristin Ladell; Phillip Scheinberg; Ethan Bornstein; David van Bockel; Anthony D Kelleher; Daniel C Douek; David A Price; Miles P Davenport
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Next-generation DNA sequencing.

Authors:  Jay Shendure; Hanlee Ji
Journal:  Nat Biotechnol       Date:  2008-10       Impact factor: 54.908

9.  Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire.

Authors:  S Verfuerth; K Peggs; P Vyas; L Barnett; R J O'Reilly; S Mackinnon
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

10.  Most alpha/beta T cell receptor diversity is due to terminal deoxynucleotidyl transferase.

Authors:  J P Cabaniols; N Fazilleau; A Casrouge; P Kourilsky; J M Kanellopoulos
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

View more
  524 in total

1.  Recovery and assessment of leukocytes from LR Express filters.

Authors:  Abby K Wegehaupt; Ellen K Roufs; Cory R Hewitt; Marisela L Killian; Oxana Gorbatenko; Cynthia M Anderson; M Scott Killian
Journal:  Biologicals       Date:  2017-07-31       Impact factor: 1.856

Review 2.  Determinants of public T cell responses.

Authors:  Hanjie Li; Congting Ye; Guoli Ji; Jiahuai Han
Journal:  Cell Res       Date:  2012-01-03       Impact factor: 25.617

Review 3.  Rep-Seq: uncovering the immunological repertoire through next-generation sequencing.

Authors:  Jennifer Benichou; Rotem Ben-Hamo; Yoram Louzoun; Sol Efroni
Journal:  Immunology       Date:  2012-03       Impact factor: 7.397

4.  Antiretroviral therapy reduces the magnitude and T cell receptor repertoire diversity of HIV-specific T cell responses without changing T cell clonotype dominance.

Authors:  Joseph A Conrad; Ramesh K Ramalingam; Coley B Duncan; Rita M Smith; Jie Wei; Louise Barnett; Brenna C Simons; Shelly L Lorey; Spyros A Kalams
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

5.  Highly diverse TCRα chain repertoire of pre-immune CD8⁺ T cells reveals new insights in gene recombination.

Authors:  Raphael Genolet; Brian J Stevenson; Laurent Farinelli; Magne Osterås; Immanuel F Luescher
Journal:  EMBO J       Date:  2012-02-28       Impact factor: 11.598

6.  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.

Authors:  Diego Chowell; Luc G T Morris; Claud M Grigg; Jeffrey K Weber; Robert M Samstein; Vladimir Makarov; Fengshen Kuo; Sviatoslav M Kendall; David Requena; Nadeem Riaz; Benjamin Greenbaum; James Carroll; Edward Garon; David M Hyman; Ahmet Zehir; David Solit; Michael Berger; Ruhong Zhou; Naiyer A Rizvi; Timothy A Chan
Journal:  Science       Date:  2017-12-07       Impact factor: 47.728

7.  CTLA4 blockade broadens the peripheral T-cell receptor repertoire.

Authors:  Lidia Robert; Jennifer Tsoi; Xiaoyan Wang; Ryan Emerson; Blanca Homet; Thinle Chodon; Stephen Mok; Rong Rong Huang; Alistair J Cochran; Begoña Comin-Anduix; Richard C Koya; Thomas G Graeber; Harlan Robins; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

8.  Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency.

Authors:  Holly K Miller; Patrick J Hanley; Haili Lang; Christopher A Lazarski; Elizabeth A Chorvinsky; Sarah McCormack; Lauren Roesch; Shuroug Albihani; Marcus Dean; Fahmida Hoq; Roberta H Adams; Catherine M Bollard; Michael D Keller
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-09       Impact factor: 5.742

9.  Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma.

Authors:  Stephan A Grupp; Eline Luning Prak; Jean Boyer; Kenyetta R McDonald; Suzanne Shusterman; Edward Thompson; Colleen Callahan; Abbas F Jawad; Bruce L Levine; Carl H June; Kathleen E Sullivan
Journal:  Clin Cancer Res       Date:  2012-10-23       Impact factor: 12.531

10.  Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I.

Authors:  Aude G Chapuis; Olga K Afanasiev; Jayasri G Iyer; Kelly G Paulson; Upendra Parvathaneni; Joo Ha Hwang; Ivy Lai; Ilana M Roberts; Heather L Sloan; Shailender Bhatia; Kendall C Shibuya; Ted Gooley; Cindy Desmarais; David M Koelle; Cassian Yee; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2014-01       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.